相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials
Alessandro Rizzo et al.
EUROPEAN UROLOGY FOCUS (2022)
The immune response to major gastrointestinal cancer surgery and potential implications for adjuvant immunotherapy
Noel E. Donlon et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)
Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy
Gary Ng et al.
CURRENT ONCOLOGY REPORTS (2022)
Current State of Adjuvant Therapy for Melanoma: Less Is More, or More Is Better?
Christopher D. Lao et al.
American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting (2022)
Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma
Alberto Martini et al.
WORLD JOURNAL OF UROLOGY (2021)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
Joaquim Bellmunt et al.
LANCET ONCOLOGY (2021)
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2021)
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J. Kelly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials
Francesco Massari et al.
EUROPEAN JOURNAL OF CANCER (2021)
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Enriqueta Felip et al.
LANCET (2021)
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
D. F. Bajorin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial
Lisa Zimmer et al.
LANCET (2020)
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2020)
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cancer and the Immune System: The History and Background of Immunotherapy
Maura Abbott et al.
SEMINARS IN ONCOLOGY NURSING (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Cancer immunoediting and resistance to T cell-based immunotherapy
Jake S. O'Donnell et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Cancer immunotherapy: broadening the scope of targetable tumours
Jitske van den Bulk et al.
OPEN BIOLOGY (2018)
Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant
Willem W. Overwijk
CURRENT OPINION IN IMMUNOLOGY (2017)
Cancer immunotherapy: harnessing the immune system to battle cancer
Yiping Yang
JOURNAL OF CLINICAL INVESTIGATION (2015)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)